Effect of Aerobic Interval Training on Atrial Fibrillation Burden
Condition(s) studied
Investigational drug(s) / intervention(s)
high-intensity interval training: high-intensity interval training : 40-50 minutes, patients engage in power cycling with intervals of high-intensity exercise at 75%-100% of VO2peak for 30s-1min, followed by 30s-1min of passive recovery, totaling 15-25 cycles.
moderate-intensity interval training: 40-50 minutes, involves power cycling with 8 minutes of moderate-intensity exercise at 40%-60% of VO2peak followed by 2 minutes of passive recovery, totaling 4 cycles.
Study summary
Atrial fibrillation is the most common arrhythmia, with an increasing incidence and prevalence, significantly increasing the risk of death, stroke, heart failure, cognitive impairment, and dementia, severely impacting the quality of life for patients and burdening society and healthcare systems. In recent years, exercise-based cardiac rehabilitation has gradually become a new approach for the treatment of patients with heart disease. The main research topics include: 1. Changes in atrial fibrillation burden in non-permanent atrial fibrillation patients after 12 weeks of HIIT(high-intensity interval training ) or MIIT (moderate-intensity interval training). 2. Changes in cardiorespiratory fitness, quality of life scores, mental health assessment scores, atrial strain, and left ventricular diastolic function in non-permanent atrial fibrillation patients after 12 weeks of aerobic interval training, along with follow-up on the occurrence of exercise-related adverse events and adverse cardiovascular events during the study period.
Eligibility
Primary outcome measure(s)
- atrial fibrillation burden — 14 weeks
The ratio of atrial fibrillation duration to total monitoring time
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Sixth Medical Center of Chinese PLA General Hospital | Beijing | Beijing Municipality |
More Navy General Hospital, Beijing trials in China
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06491329 on ClinicalTrials.gov ↗ ← All trials in China